Merrimack Pharmaceuticals, Inc.
MACK
MACK was delisted on the 17th of May, 2024.
143 hedge funds and large institutions have $657M invested in Merrimack Pharmaceuticals, Inc. in 2014 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 45 increasing their positions, 44 reducing their positions, and 20 closing their positions.
65% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 20
39% more capital invested
Capital invested by funds: $474M → $657M (+$183M)
8% more funds holding
Funds holding: 132 → 143 (+11)
2% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 44
31% less call options, than puts
Call options by funds: $1.79M | Put options by funds: $2.58M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.22M |
| 2 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$6.6M |
| 3 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$5.39M |
| 4 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$4.41M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$3.74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$13.5M |
| 2 |
State Street
Boston,
Massachusetts
|
-$4.29M |
| 3 |
Jane Street
New York
|
-$2.83M |
| 4 |
SIP
Stoneridge Investment Partners
Radnor,
Pennsylvania
|
-$2.59M |
| 5 |
New York State Common Retirement Fund
Albany,
New York
|
-$1.94M |
MACK Hedge Fund Activity: Q4 2014 in Review
143 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q4 2014, worth a combined $657M — up 39% from $474M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new MACK positions and 20 closed out — a net gain of 13 holders — while 45 added to existing stakes and 44 trimmed.
The largest buyer was Vanguard Group, adding an estimated $9.22M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $13.5M sold.
- 143 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q4 2014, up from 132 in Q3 2014.
- Funds reported $657M of Merrimack Pharmaceuticals, Inc. stock for Q4 2014, up 39% quarter-over-quarter.
- 33 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q4 2014 and 20 closed out, a net change of +13 holders.
- The largest Merrimack Pharmaceuticals, Inc. buyer in Q4 2014 was Vanguard Group, an estimated $9.22M added.
- The largest Merrimack Pharmaceuticals, Inc. seller in Q4 2014 was Consonance Capital Management, an estimated $13.5M sold.
Based on aggregated 13F filings for Q4 2014.